{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Ovarian&page=6",
    "query": {
      "condition": "Carcinoma, Ovarian",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 2184,
    "total_pages": 219,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Ovarian&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Ovarian&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:50:42.018Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02781272",
      "title": "Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pelvic imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Blood draw",
          "type": "PROCEDURE"
        },
        {
          "name": "Imaging guided biopsy, surgical biopsy or surgical excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Angle plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 200,
      "start_date": "2016-06-30",
      "completion_date": "2022-06-27",
      "has_results": false,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781272"
    },
    {
      "nct_id": "NCT02081495",
      "title": "A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "DOXIL/CAELYX reference product (Treatment A)",
          "type": "DRUG"
        },
        {
          "name": "DOXIL/CAELYX test product (Treatment B)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2014-08",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-11",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02081495"
    },
    {
      "nct_id": "NCT04407611",
      "title": "Scalable Communication Modalities for Returning Genetic Research Results",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hereditary Breast and Ovarian Cancer",
        "Lynch Syndrome"
      ],
      "interventions": [
        {
          "name": "Online modality",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Genetic counselor follow-up",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 926,
      "start_date": "2023-03-06",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04407611"
    },
    {
      "nct_id": "NCT03113487",
      "title": "P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Platinum-Resistant Fallopian Tube Carcinoma",
        "Recurrent Platinum-Resistant Ovarian Carcinoma",
        "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Modified Vaccinia Virus Ankara Vaccine Expressing p53",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2018-02-01",
      "completion_date": "2027-04-08",
      "has_results": true,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113487"
    },
    {
      "nct_id": "NCT06268665",
      "title": "Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Stage I",
        "Breast Cancer Stage II",
        "Breast Cancer Stage III",
        "Breast Cancer Stage IV",
        "Invasive Breast Cancer",
        "Ovarian Cancer",
        "Ovarian Cancer Stage 1",
        "Ovarian Cancer Stage II",
        "Ovarian Cancer Stage III",
        "Ovarian Cancer Stage IV",
        "Ovarian Cancer Stage IA",
        "Ovarian Cancer Stage IB",
        "Ovarian Cancer Stage IC",
        "Ovarian Cancer Stage 2",
        "Ovarian Cancer Stage 3",
        "Ovarian Cancer Stage IIIb",
        "Ovarian Cancer Stage IIIC",
        "Breast Cancer Stage IIIA",
        "Breast Cancer Invasive",
        "Breast Cancer, Stage IA",
        "Breast Cancer, Stage IB",
        "Breast Cancer Stage IIA",
        "Breast Cancer Stage IIB",
        "Breast Cancer Stage IIIB",
        "Breast Cancer Stage IIIc",
        "Cancer, Breast",
        "Tumors, Breast",
        "Mammary Cancer",
        "Mammary Carcinoma",
        "Breast Carcinoma",
        "Breast Neoplasm",
        "Malignant Breast Neoplasm",
        "Malignant Tumor of Breast",
        "Cancer of Ovary",
        "Ovary Cancer",
        "Ovary Neoplasm"
      ],
      "interventions": [
        {
          "name": "Tart Cherry Juice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2024-08-15",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06268665"
    },
    {
      "nct_id": "NCT00002671",
      "title": "Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "aminocamptothecin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "1995-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2012-11-09",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 6,
      "location_summary": "Red Bank, New Jersey • Summit, New Jersey • New York, New York + 1 more",
      "locations": [
        {
          "city": "Red Bank",
          "state": "New Jersey"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002671"
    },
    {
      "nct_id": "NCT05922930",
      "title": "Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "Ovarian Cancer",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "TROP2-CAR-NK",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2023-10-11",
      "completion_date": "2028-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05922930"
    },
    {
      "nct_id": "NCT00413075",
      "title": "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "oral belinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2006-06",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413075"
    },
    {
      "nct_id": "NCT07224464",
      "title": "The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Stage 4 Cancer"
      ],
      "interventions": [
        {
          "name": "The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "New Phase Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-12-16",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224464"
    },
    {
      "nct_id": "NCT00738699",
      "title": "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "MORAb-003 (farletuzumab)",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Morphotek",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 99 Years · Female only"
      },
      "enrollment_count": 415,
      "start_date": "2008-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-10-14T16:50:42.018Z",
      "location_count": 34,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738699"
    }
  ]
}